Bullish case
$140 to $155
More likely if Medical Devices keeps high single-digit growth, Libre and electrophysiology regain momentum, Nutrition volumes recover, Exact Sciences adds durable growth, and leverage falls without cutting R&D intensity.
Abbott Laboratories research snapshot
ABT AI Stock Analysis
ABT AI stock analysis currently reads Abbott Laboratories as a diversified healthcare company with durable medical device, diagnostics, nutrition, and established pharmaceuticals franchises, but with valuation, post-Exact Sciences leverage, Nutrition reset, and diabetes care growth risks still important. At the July 8, 2026 data cutoff, ABT traded near $95.84 with a verified market capitalization near $166.94 billion. This analysis uses scenario ranges and source checks, not a certain price prediction, and is for informational use only.
Current price
$95.84
Market cap
$166.94 billion
AI score
66 / 100
Rating
Diversified healthcare compounder, leverage watch
Trend status
Short-term recovery below the long-term moving average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Abbott has long public filings, company earnings releases, investor materials, technical data providers, and multiple third-party financial datasets.
- bias Check
- The main AI bias risk is repeating the consensus quality-compounder narrative. The reverse check focuses on whether Exact Sciences integration raises debt risk, whether Nutrition volumes recover after pricing changes, and whether Libre and broader MedTech growth can offset Diagnostics normalization.
- ai Confidence
- High for filings, FY2025 financials, Q1 2026 results, market cap math, and common valuation ratios. Medium for forward valuation because product cycles, reimbursement, litigation, currency, and acquisition financing can change quickly.
- investment Certainty
- Medium. Abbott is easier to research than many healthcare names because of its scale and disclosure, but the current price still requires confidence in execution, balance sheet repair, and steady mid single-digit to high single-digit growth.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Abbott sells essential healthcare products across Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals, with demand spread across hospitals, patients, labs, and global consumer health channels. | High |
| Moat | Moat comes from regulated products, clinical data, installed systems, global distribution, manufacturing scale, product brands, and switching costs in devices and diagnostics. | Medium-high |
| Management | Management has a long record of portfolio shaping and dividend growth, but current capital allocation should be judged by Exact Sciences integration, debt reduction, and R&D productivity. | Medium |
| Financial trend | FY2025 sales grew 5.7% to $44.328 billion, while Q1 2026 sales grew 7.8% reported and adjusted EPS was $1.15. | High |
| Valuation | Using the $5.48 midpoint of updated 2026 adjusted EPS guidance, the stock traded near 17.5x forward adjusted EPS and 22.6x FY2025 free cash flow per share. | Medium-high |
| Technical trend | ABT is above short-term moving averages near $89 to $91, but still below common 200-day moving average snapshots near $111. | Medium |
| Risk level | Key risks include acquisition leverage, diagnostics growth normalization, Nutrition volume recovery, reimbursement pressure, product quality issues, currency, and medtech competition. | Medium-high |
| AI confidence | High for descriptive facts and audited math. Lower for forecast ranges because healthcare multiples and product growth can reprice fast after earnings or regulatory news. | High data confidence |
| Investment certainty | Medium certainty. The page gives a research framework and scenario ranges, not a buy or sell instruction. | Medium |
ABT AI stock forecast
ABT AI Stock Forecast Scenarios
The ABT AI stock forecast uses scenario math around the $95.84 quote and Abbott managements updated 2026 adjusted EPS guidance. Using the $5.48 midpoint of adjusted EPS guidance, the audited three-year framework produced a bearish area near $81, a base area near $118, and a bullish area near $149 before dividends.
Base case
$110 to $125
More likely if Abbott compounds adjusted EPS around the mid single digits, maintains strong free cash flow conversion, and the market applies an earnings multiple in the high teens.
Bearish case
$75 to $85
More likely if acquisition debt constrains capital returns, Nutrition stays weak, Diagnostics growth remains low, Libre competition intensifies, or investors assign a lower multiple to slower healthcare growth.
ABT AI technical analysis
ABT AI Technical Analysis
ABT AI technical analysis is mixed as of the July 8, 2026 data cutoff. The stock recovered above short-term and 50-day moving averages near $89 to $91, but several technical snapshots still placed the 200-day moving average near $111, which keeps the longer trend unresolved.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $95.84 | Yahoo Finance and Abbott investor quote snapshots were used around the July 8, 2026 cutoff. |
| Near support | $88.93 to $90.94 | TipRanks and Barchart snapshots placed the 20-day and 50-day moving averages in this zone. |
| Deeper support | $81.97 | Recent quote data listed this as the 52-week low. A retest would signal a failed recovery. |
| Near resistance | $97 to $100 | This is the immediate round-number area above the current quote and recent intraday range. |
| Long-term resistance | $110.95 to $111.64 | TipRanks and Barchart listed 200-day moving average snapshots in this zone, making it a key trend test. |
| Momentum | RSI roughly 63 | TipRanks and Barchart showed neutral to firm RSI readings, not a deeply oversold setup. |
| Volume | Average volume near 13 million shares | Recent quote and technical sources showed average volume around 13 million shares, useful for judging breakout quality. |
| Volatility | $81.97 to $137.49 52-week range | The wide range shows that earnings, guidance, and acquisition news can materially reset the stock. |
| Invalidation | Close below $88 | A decisive close below the short-term moving average cluster would weaken the recovery setup. |
ABT AI trading strategy
ABT AI Trading Strategy Framework
The ABT AI trading strategy is a rules-based research framework for monitoring a healthcare quality stock after a drawdown and acquisition reset. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
Trend-following setup
Watch for ABT to hold above the $89 to $91 moving average cluster, then reclaim the $97 to $100 area on volume above average. A later test of the $111 area would be the bigger long-term trend check.
A close below $88 or a failed reclaim after the next earnings update should invalidate the near-term recovery setup.
Mean-reversion setup
If ABT pulls back toward the $89 to $91 support zone without fresh balance sheet or guidance damage, compare the price reaction with Q2 results, Libre growth, Nutrition volume data, and debt metrics.
Do not average down without a maximum loss rule because healthcare stocks can gap on product, legal, regulatory, or reimbursement news.
Fundamental monitor
Track comparable sales growth, adjusted EPS guidance, free cash flow, Exact Sciences integration costs, total debt, Libre growth, Medical Devices margins, and Nutrition volume recovery.
Reduce confidence if EPS growth depends mainly on adjustments or financial leverage instead of organic demand and cash generation.
Investment research summary
Four-master Research Compression
Business essence
Abbott turns regulated healthcare science, device engineering, diagnostics platforms, nutrition brands, and emerging market pharmaceuticals into recurring demand from patients, clinicians, labs, and caregivers.
Moat
The moat is portfolio-based. Clinical validation, regulatory approvals, device training, channel access, manufacturing scale, and trusted brands make fast replication difficult, though no single line is immune from competition.
Munger risk inversion
The thesis fails if debt from Exact Sciences limits flexibility, Libre growth slows faster than expected, Nutrition does not recover, Diagnostics stays ex-growth, or pricing and reimbursement pressure compress margins.
Management
Management should be measured by portfolio discipline, integration execution, R&D return, debt reduction, dividend coverage, and willingness to protect long-term product investment over short-term EPS optics.
Industry trend
Abbott sits inside long-duration healthcare demand from aging populations, chronic disease, diabetes monitoring, diagnostics, and global access to branded generic medicines.
Valuation and margin of safety
At about 17.5x updated 2026 adjusted EPS guidance, valuation is less demanding than many healthcare compounders, but margin of safety depends on restoring growth while absorbing acquisition debt.
Source-backed data
ABT Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ABT price | $95.84 | Yahoo Finance quote snapshot | July 8, 2026 |
| Market capitalization | $166.94 billion, verified as $95.84 x 1.741813154 billion shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $44.328 billion, cross-checked against third-party $44.3 billion figures | Abbott FY2025 results release and StockTitan cross-check | July 8, 2026 |
| FY2025 net income | $6.524 billion | Abbott 2025 Annual Report and Macrotrends cross-check | July 8, 2026 |
| FY2025 free cash flow | $7.395 billion | Macrotrends free cash flow data | July 8, 2026 |
| Q1 2026 sales and adjusted EPS | $11.16 billion sales, $1.15 adjusted diluted EPS | Abbott Q1 2026 results release | July 8, 2026 |
| 2026 adjusted EPS guidance | $5.38 to $5.58, including $0.20 dilution from Exact Sciences | Abbott Q1 2026 results release | July 8, 2026 |
| Cash and total debt | $7.30 billion cash and $34.14 billion total debt, MRQ | StockAnalysis and Yahoo Finance key statistics cross-check | July 8, 2026 |
| Valuation check | 17.49x forward adjusted EPS, 3.21x book, 22.58x FY2025 free cash flow per share, 2.63% dividend yield | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 20-day SMA near $90.94, 50-day SMA near $88.93 to $89.00, 200-day SMA near $110.95 to $111.64, RSI near 63 | Barchart and TipRanks technical snapshots | July 8, 2026 |
Frequently Asked Questions
Read the MMM AI stock analysisView T AI stock forecastExplore GOOG AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This ABT AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, product news, acquisition updates, market moves, or macro conditions.